The applicable population range of Trelagliptin and the key points of health assessment before use

Trelagliptin (Trelagliptin) is a new type of dipeptidyl peptidase-4 (DPP-4) inhibitor, mainly used for treatment Patients with type 2 diabetes (T2DM) can improve blood sugar control by prolonging the activity of insulin secretion-stimulating peptide (GLP-1). The drug is suitable for use as monotherapy or in combination with other oral hypoglycemic drugs, especially for adult patients who have insufficient blood sugar control through diet and exercise. Trelagliptin has the characteristics of long duration of action and only needs to be taken once a day, which improves patient compliance.

Before using trotagliptin, patients need to undergo a comprehensive health assessment to ensure the safety of the medication. Renal function should be assessed first, because trotagliptin is mainly excreted by the kidneys. For patients with moderate to severe renal insufficiency, the dose needs to be adjusted based on renal function or used with caution. Patients with abnormal liver function also need to pay attention to drug metabolism and potential risks, and liver function tests should be performed first if necessary.

In addition, patients should be screened for a history of hypoglycemia risk or current use of medications that may cause hypoglycemia (such as sulfonylureas or insulin). Although the risk of hypoglycemia is low when trotagliptin is used alone, it may increase the incidence of hypoglycemia when used in combination with other antidiabetic drugs. Blood glucose monitoring, lifestyle management, and educating patients to recognize symptoms of hypoglycemia are all important aspects of health assessment.

Finally, tretagliptin is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Therefore, the type of diabetes and recent changes in condition should be clarified before use. At the same time, you should know whether the patient has a history of pancreatitis or pancreatic disease, because DPP-4 inhibitor drugs may have a risk of pancreatitis. Comprehensive evaluation of cardiovascular history, renal and liver function, blood sugar control and medication history can provide scientific basis for the safe use of trotagliptin and improve the therapeutic effect.

Reference link:https://www.drugs.com